Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have earned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, MarketBeat reports.

Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and ...

Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), a biopharmaceutical company focused on rare liver diseases, has been making significant strides in its product portfolio and market position. With a market ...

He mentioned that Borneo Pharmaceuticals PNG have also returned to the fold for the 2025 season, plus Allied Security Solutions. “So far it is all positive as we look to complete the 9s this weekend ...

On Tuesday, 11 March 2025, Mirum Pharmaceuticals (NASDAQ: MIRM) participated in the Leerink’s Global Healthcare Conference 2025, where CEO Chris Pietz outlined the company’s strategic direction. The ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors granted ...

FOSTER CITY, Calif., March 11, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2025, the Compensation Committee of Mirum’s Board of Directors ...

“Under the theme “Designing Future Society for Our Lives,” the Expo will address eight key thematic areas focused on global challenges, providing an exceptional platform for PNG to showcase its trade ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...